Janux Therapeutics, Inc. $JANX Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its stake in Janux Therapeutics by 26.5% during the first quarter, holding 393,477 shares worth approximately $10.6 million after selling off 141,919 shares.
• Multiple institutional investors showcased significant activity, with GAMMA Investing LLC raising its holdings by 1,574%, while US Bancorp DE grew its position by 2,402.9% during the same period.
• Janux Therapeutics reported an earnings per share of ($0.55), missing analysts' estimates, and has an average rating of "Buy" with a consensus target price of $86.90.

Wellington Management Group LLP cut its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 26.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 393,477 shares of the company's stock after selling 141,919 shares during the period. Wellington Management Group LLP owned 0.67% of Janux Therapeutics worth $10,624,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. RA Capital Management L.P. grew its stake in shares of Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after buying an additional 1,200,000 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after acquiring an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its holdings in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after acquiring an additional 1,115,412 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Janux Therapeutics by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock valued at $61,524,000 after acquiring an additional 142,328 shares in the last quarter. Finally, Woodline Partners LP lifted its holdings in shares of Janux Therapeutics by 15.7% during the 4th quarter. Woodline Partners LP now owns 1,852,187 shares of the company's stock valued at $99,166,000 after acquiring an additional 251,924 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Up 0.6%

Shares of JANX traded up $0.14 during midday trading on Tuesday, hitting $22.86. The company had a trading volume of 904,571 shares, compared to its average volume of 787,388. The company's 50 day moving average price is $24.50 and its 200 day moving average price is $26.96. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -12.70 and a beta of 2.84. Janux Therapeutics, Inc. has a 52 week low of $21.97 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JANX. Piper Sandler began coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $42.00 target price on the stock. Raymond James Financial began coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They set an "outperform" rating and a $65.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $86.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.